

[Docket No. 81F-0414]**Borg-Warner Chemicals, Inc.; Filing of Food Additive Petition**

AGENCY: Food and Drug Administration.
ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Borg-Warner Chemicals, Inc., has filed a petition proposing that the food additive regulations be amended to provide for the safe use of phosphorous acid, cyclic neopentetetrayl bis(2,4-di-tert-butylphenyl) ester with triisopropanolamine as an antioxidant and/or stabilizer in polyvinyl chloride and vinyl chloride copolymers in contact with food.

FOR FURTHER INFORMATION CONTACT: James H. Maryanski, Bureau of Foods (HFF-334), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202-472-5690.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5), 72 Stat. 1786 (21 U.S.C. 348(b)(5))), notice is given that a petition (FAP 2B3598) has been filed by Borg-Warner Chemicals, Inc., Technical Centre, Washington, WV 26181, proposing that § 178.2010 *Antioxidants and/or stabilizers for polymers* (21 CFR 178.2010) be amended to provide for the safe use of phosphorous acid, cyclic neopentetetrayl bis(2,4-di-tert-butylphenyl) ester with triisopropanolamine as an antioxidant and/or stabilizer in polyvinyl chloride and vinyl chloride copolymers in contact with food.

The potential environmental impact of this action is being reviewed. If the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the Federal Register in accordance with 21 CFR 25.40(c) (proposed December 11, 1979; 44 FR 71742).

Dated: January 20, 1982.

Sanford A. Miller,
Director, Bureau of Foods.

[FR Doc. 82-2099 Filed 1-28-82; 8:45 am]

BILLING CODE 4160-01-M

Consumer Participation; Open Meetings

AGENCY: Food and Drug Administration.
ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the following consumer exchange meetings:

Detroit District Office, Chaired by Alan L. Hoeting, District Director

Date: Tuesday, February 9, 1982, 9:30 a.m.
 Address: George Potter Harrick Bldg., Conference Rm., 1560 E. Jefferson, Detroit, MI 48207.

For further information contact: Diane M. Place, Consumer Affairs Officer, Food and Drug Administration, 1560 E. Jefferson, Detroit, MI 48207, 313-226-6260.

Orlando District Office, Chaired by Adam J. Trujillo, District Director

Date: Thursday, February 11, 1982, 1:30 p.m.
 Address: Hillsborough Community College, Dale Mabry Campus, Humanities Bldg., Rm. 118, 4001 Tampa Bay Blvd., Tampa, FL 33607.

For further information contact: Nellie Mendez, Consumer Affairs Officer, Food and Drug Administration, 6501 NW 36th St., Suite 200, Miami, FL 33166, 305-526-2920.

Newark District Office, Chaired by Matthew H. Lewis, District Director

Date: Thursday, February 25, 1982, 10 a.m.
 Address: Rutgers University, Labor Education Center, Cook Campus, New Brunswick, NJ 08903.

For further information contact: Lillie Dortch-Wright, Consumer Affairs Officer, Food and Drug Administration, 20 Evergreen Place, East Orange, NJ 07018, 201-645-3265.

SUPPLEMENTARY INFORMATION: The purpose of these meetings is to encourage dialogue between consumers and FDA officials, to identify and set priorities for current and future health concerns, to enhance understanding and exchange information between local consumers and FDA's District Offices, and to contribute to the agency's policymaking decisions on vital issues.

Dated: January 22, 1982.

William F. Randolph,
Acting Associate Commissioner for Regulatory Affairs.

[FR Doc. 82-2100 Filed 1-28-82; 8:45 am]

BILLING CODE 4160-01-M

[Docket No. 80F-0027]**Lonza, Inc.; Withdrawal of Petition for Food Additives**

AGENCY: Food and Drug Administration.
ACTION: Notice

SUMMARY: The Food and Drug Administration (FDA) is announcing the withdrawal without prejudice of Citizen Petition OCP 3488, which requests that FDA reverse its determination that use of quaternary alkyl dimethylammonium compounds derived from olefin-based amines is permissible under § 178.1010 (21 CFR 178.1010).

FOR FURTHER INFORMATION CONTACT: James B. Lamb, Bureau of Foods (HFF-

334), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202-472-5690.

SUPPLEMENTARY INFORMATION: Under sections 409(h) and 701(e)(1) of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 348(h) and 371(e)), FDA issues the following notice:

In accordance with paragraph (g) of § 10.30 of FDA's procedural regulations (21 CFR 10.30(g)), Lonza, Inc., Fair Lawn, NJ 07410, has withdrawn its petition (OCP 3488) that requests that FDA reverse its determination that quaternary alkyl dimethylammonium compounds derived from olefin-based amines will be regulated in the same manner as those derived from fatty acids. Notice of Lonza's petition was published in the Federal Register of February 22, 1980 (45 FR 11909). Lonza, Inc., withdrew its petition in a letter dated October 30, 1981.

Dated: January 20, 1982.

Sanford A. Miller,
Director, Bureau of Foods.

[FR Doc. 82-2096 Filed 1-28-82; 8:45 am]

BILLING CODE 4160-01-M

Vaccines and Related Biological Products Advisory Committee; Notice of Renewal

AGENCY: Food and Drug Administration.
ACTION: Notice.

SUMMARY: Under the Federal Advisory Committee Act of October 6, 1972 (Pub. L. 92-463, 86 Stat. 770-776 (5 U.S.C. App. I)), the Food and Drug Administration announces the renewal of the Vaccines and Related Biological Products Advisory Committee by the Secretary, Department of Health and Human Services.

DATE: Authority for this committee will expire on December 31, 1983, unless the Secretary formally determines that renewal is in the public interest.

FOR FURTHER INFORMATION CONTACT: Richard L. Schmidt, Committee Management Office (HFA-306), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-443-2765.

Dated: January 22, 1982.

William F. Randolph,
Acting Associate Commissioner for Regulatory Affairs.

[FR Doc. 82-2098 Filed 1-28-82; 8:45 am]

BILLING CODE 4160-01-M

[Docket No. 81N-0302; DESI 5914, 6303, 6340, 6514, 7937, and 8658]

Certain Oral Prescription Drugs Offered for Relief of Symptoms of Cough, Cold, or Allergy ("Paragraph XIV/Category 15") Which Are No Longer Marketed; Drugs for Human Use; Drug Efficacy Study Implementation; Revocation of Exemption; Followup Notice and Opportunity for Hearing

AGENCY: Food and Drug Administration.
ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) revokes the temporary exemption for certain oral prescription drugs offered for relief of symptoms of cough, cold, or allergy, which permitted the products to remain on the market beyond the time limit scheduled for implementation of the Drug Efficacy Study. FDA reclassifies the products to lacking substantial evidence of effectiveness and offers an opportunity for a hearing on a proposal to withdraw approval of the new drug applications of these no longer marketed products.

DATES: Revocation of exemption effective January 29, 1982. Hearing requests due on or before March 6, 1982.

ADDRESSES: Communications in response to this notice should be identified with Docket No. 81N-0302, directed to the attention of the appropriate office named below, and addressed to the Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857.

Requests for opinion of the applicability of this notice to a specific product: Division of Drug Labeling Compliance (HFD-310), Bureau of Drugs.

Other communications regarding this notice: Drug Efficacy Study Implementation Project Manager (HFD-501), Bureau of Drugs.

Requests for the report of the National Academy of Sciences-National Research Council: Public Records and Document Center (HFI-35), Rm. 12A-12.

Requests for hearing, supporting data, and other comments: Dockets Management Branch (formerly the Hearing Clerk's office) (HFA-305), Rm. 4-62.

FOR FURTHER INFORMATION CONTACT: David T. Read, Bureau of Drugs (HFD-32), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-443-3650.

SUPPLEMENTARY INFORMATION: In notices published in the Federal Register (DESI 5914 on February 9, 1973 (38 FR 4008); DESI 6303 on May 22, 1971 (36 FR 9339), amended on March 19, 1973 (38 FR

7265); DESI 6340 on February 27, 1971 (36 FR 3832); DESI 6514 on February 9, 1973 (38 FR 4006); DESI 7937 on June 6, 1972 (37 FR 11277); DESI 8658 on February 9, 1973 (38 FR 4005)), FDA classified the drug products described below as less than effective for their labeled indications (probably effective, possibly effective, and lacking substantial evidence of effectiveness).

In a notice published in the Federal Register of December 14, 1973 (38 FR 34481), FDA granted a temporary exemption from the time limits established for completing certain phases of the drug efficacy study (DESI) program, for certain oral prescription drugs offered for relief of cough, cold, allergy, and related symptoms. That exemption covered the drug products that are the subject of this notice and superseded the notices of opportunity for hearing published earlier. The exemption was granted because of the close relationship between drugs sold over the counter (OTC)—and thus subject to the ongoing OTC drug review (21 CFR Part 330)—and prescription drugs offered for relief of cough, cold, allergies, and related symptoms. Postponement of final evaluations on the DESI prescription products enabled the agency to consider the recommendations of the OTC review panel in addition to any evidence submitted by NDA holders in response to various DESI notices covering relevant products. Those recommendations and a proposed monograph for over-the-counter cold, cough, allergy, bronchodilator, and antiasthmatic (CCABA) drugs were published in the Federal Register on September 9, 1976 (41 FR 38312).

No person has submitted additional data on the drug products listed below, and none of them is marketed any longer. Therefore the Director of the Bureau of Drugs has reclassified them to lacking substantial evidence of effectiveness. He concludes that these evaluations are not inconsistent with the recommendations of the OTC review panel. The Director notes that some of these products contain an ingredient already concluded to be effective when offered as a single active ingredient product or in conventional release dosage form. These products, however, lack evidence of effectiveness either as combination products (in which each ingredient has not been shown to contribute to the claimed effect) or as controlled release products (for which the claimed effects have not been substantiated).

This notice revokes the temporary exemption announced in the Federal Register of December 14, 1973, and

offers an opportunity for hearing on the proposal to withdraw approval of the following combination products. The proposal regarding these products does not affect any single entity product, and affects other combination products only if they are identical or substantially similar or related to the following. Persons who wish to request a hearing may do so on or before March 1, 1982.

1. NDA 5-914: as it pertains to Pyribenzamine Expectorant with Codeine and Ephedrine, containing tripeleminamine citrate, codeine phosphate, ephedrine sulfate, and ammonium chloride; Ciba Pharmaceutical Co., 556 Morris Ave., Summit, NJ 07901. (DESI 5914).

2. NDA 6-340: as it pertains to Histadyl and Ephedrine Hydrochloride Pulvules No. 1 and No. 2, containing methapyrilene hydrochloride and ephedrine hydrochloride; Eli Lilly and Co., 740 S. Alabama St., Box 618, Indianapolis, IN 46206. (DESI 6340).

3. NDA 8-658: Coricidin with Codeine Phosphate Tablets, containing chlorpheniramine maleate, codeine phosphate, aspirin, phenacetin, and caffeine; Schering Corp., Galloping Hill Rd., Kenilworth, NJ 07033. (DESI 8658).

4. NDA 8-670: Phenergan Expectorant Troches with Codeine, containing codeine phosphate, promethazine hydrochloride, ipecac powdered extract, and potassium guaiacolsulfonate; Wyeth Laboratories, Inc., Division of American Home Products Corp., P.O. Box 8299, Philadelphia, PA 19101. (DESI 6514).

5. NDA 8-893: Phenergan Expectorant Troches Plain, containing promethazine hydrochloride, ipecac powdered extract, and potassium guaiacolsulfonate; Wyeth Laboratories, Inc. (DESI 6514).

6. NDA 11-536: Kryl Tablets, containing isothipendyl hydrochloride, aspirin, phenacetin, phenylephrine hydrochloride, and ascorbic acid; Ayerst Laboratories, Division of American Home Products Corp., 685 Third Ave., New York, NY 10017. (DESI 6340).

7. NDA 12-909: Ulominic Syrup, containing chlophedianol hydrochloride, diphenylpyraline hydrochloride, phenylephrine hydrochloride, and guaifenesin (name previously used: glyceryl guaiacolate); Riker Laboratories, Inc., Subsidiary of 3M Company, 19901 Nordhoff St., Northridge, CA 91324. (DESI 6514).

8. NDA 12-910: Ulogesic Tablets, containing acetaminophen, chlophedianol hydrochloride, diphenylpyraline hydrochloride, phenylephrine hydrochloride, and guaifenesin (name previously used: glyceryl guaiacolate); Riker Laboratories, Inc. (DESI 6514).

This notice also revokes the temporary exemption announced in the Federal Register of December 14, 1973, and offers an opportunity for hearing on the proposal to withdraw approval of the following controlled release products. This notice does not affect the status of conventional release forms of these drugs. Persons who wish to request a hearing may do so on or before March 1, 1982.

1. NDA 10-395: Histionex 50 Capsules, containing phenyltoloxamine as a cation exchange resin complex of sulfonated polystyrene; Pennwalt Corp., Pharmaceutical Division, Jefferson Rd., Rochester, NY 14623. (DESI 7937).

2. NDA 11-905: Disomer Chronotabs, sustained release tablets containing dexbrompheniramine maleate; Schering Corp. (DESI 6303).

(Approval of two of these new drug applications was previously withdrawn: NDA 10-395 on June 7, 1977 (42 FR 29104) for failure to file reports required by section 505(j) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(j)); NDA 8-658 on February 22, 1980 (45 FR 11910) based on the written request of the applicant who no longer markets the drug. At the time those two notices were published, the FDA had made no final conclusions concerning the effectiveness of the relevant products. This notice informs all interested persons, including any who market an identical, similar, or related drug product, of the conclusions which have now been reached.)

In addition to the holders of the new drug applications specifically named above, this notice applies to any person who manufactures or distributes a drug product, not the subject of an approved new drug application, that is identical, related, or similar (as limited above) to a drug product named above, as defined in 21 CFR 310.6. It is the responsibility of every drug manufacturer or distributor to review this notice to determine whether it covers any drug product that the person manufactures or distributes. Any person may request an opinion of the applicability of this notice to a specific drug product by writing to the Division of Drug Labeling Compliance (address given above).

On the basis of all the data and information available to him, the Director of the Bureau of Drugs is unaware of any adequate and well-controlled clinical investigation, conducted by experts who are qualified by scientific training and experience, that meets the requirements of section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355) and 21 CFR 314.111(a)(5) and, for combination products, 21 CFR 300.50, and

demonstrates the effectiveness of the drug products referred to in this notice.

Notice is given to the holders of the new drug applications, and to all other interested persons, that the Director of the Bureau of Drugs proposes to issue an order under section 505(e) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(e)), withdrawing approval of the new drug applications (except NDA 10-395 and NDA 8-658) and all amendments and supplements thereto providing for the drugs referred to in this notice on the ground that new information before him with respect to the drug products, evaluated together with the evidence available to him when the applications were approved, shows there is a lack of substantial evidence that the drug products will have any of the effects they purport or are represented to have under the conditions of use prescribed, recommended, or suggested in the labeling.

This notice of opportunity for hearing encompasses all issues relating to the legal status of the drug products subject to it (including identical, related, or similar drug products as defined in 21 CFR 310.6), e.g., any contention that any such product is not a new drug because it is generally recognized as safe and effective within the meaning of section 201(p) of the act or because it is exempt from part or all of the new drug provisions of the act under the exemption for products marketed before June 25, 1938, in section 201(p) of the act, or under section 107(c) of the Drug Amendments of 1962, or for any other reason.

In accordance with section 505 of the act (21 U.S.C. 355) and the regulations promulgated under it (21 CFR Parts 310, 314), the applicants and all other persons who manufacture or distribute a drug product that is identical, related, or similar (as limited above) to a drug product named above (21 CFR 310.6) and not the subject of a new drug application, are hereby given an opportunity for a hearing to show why approval of the new drug applications should not be withdrawn and an opportunity to raise, for administrative determination, all issues relating to the legal status of a drug product named above and all identical, related, or similar drug products not the subject of a new drug application.

An applicant or other person subject to this notice under 21 CFR 310.6 who decides to seek a hearing shall file (1) on or before March 1, 1982, a written notice of appearance and request for hearing, and (2) on or before March 30, 1982, the data, information, and analyses relied

on to justify a hearing, as specified in 21 CFR 314.200. Any other interested person may also submit comments on this proposal to withdraw approval. The procedures and requirements governing this notice of opportunity for hearing, a notice of appearance and request for hearing, a submission of data, information, and analyses to justify a hearing, other comments, and a grant or denial of hearing, are contained in 21 CFR 314.200.

The failure of an applicant or any other person subject to this notice under 21 CFR 310.6 to file a timely written notice of appearance and request for hearing as required by 21 CFR 314.200 constitutes an election by the person not to make use of the opportunity for a hearing concerning the action proposed, and a waiver of any contentions concerning the legal status of the relevant drug product. Any such drug product may not thereafter lawfully be marketed, and the Food and Drug Administration will initiate appropriate regulatory action to remove such drug products from the market. Any new drug product marketed without an approved NDA is subject to regulatory action at any time.

A request for a hearing may not rest upon mere allegations or denials, but must present specific facts showing that there is a genuine and substantial issue of fact that requires a hearing. If it conclusively appears from the face of the data, information, and factual analyses in the request for hearing that there is no genuine and substantial issue of fact which requires a hearing to determine the legal status of any of the drug products affected by this notice, or when a request for hearing is not made in the required format or with the required analyses, the Commissioner of Food and Drugs will enter summary judgment against the person(s) who requests the hearing, making findings and conclusions, and denying a hearing.

All submissions pursuant to this notice are to be filed in four copies. Except for data and information prohibited from public disclosure under 21 U.S.C. 331(j) or 18 U.S.C. 1905, the submissions may be seen in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday.

This notice is issued under the Federal Food, Drug, and Cosmetic Act (secs. 502, 505, 52 Stat. 1050-1053, as amended (21 U.S.C. 352, 355)) and under the authority delegated to the Director of the Bureau of Drugs (21 CFR 5.70 and 5.82).

Dated: January 8, 1982.
J. Richard Crout,
Director, Bureau of Drugs.
 [FR Doc. 82-2289 Filed 1-28-82; 8:45 am]
 BILLING CODE 4160-01-M

[Docket No. 81F-0409]

Dow Chemical Co.; Filing of Food Additive Petition

AGENCY: Food and Drug Administration.
ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Dow Chemical Co. has filed a petition proposing that the food additive regulations be amended to provide for the safe use of hydroxypropyl methylcellulose as a nonnutritive additive to confectionery products.

FOR FURTHER INFORMATION CONTACT: Julius Smith, Bureau of Foods (HFF-334), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202-472-5690.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5), 72 Stat. 1786 (21 U.S.C. 348(b)(5))), notice is given that a petition (FAP 7A3252) has been filed by Dow Chemical Co., Midland, MI 48640, proposing that § 172.874 (21 CFR 172.874) be amended to provide for the safe use of hydroxypropyl methylcellulose as a nonnutritive additive to confectionery products.

The agency has carefully considered the potential environmental effects of this action and has concluded that the action will not have a significant impact on the human environment and that an environmental impact statement is not required. The agency's finding of no significant impact and the evidence supporting that finding may be seen in the Dockets Management Branch (HFA-305), Food and Drug Administration, Rm. 4-62, 5600 Fishers Lane, Rockville, MD 20857, between 9 a.m. and 4 p.m., Monday through Friday.

Dated: January 20, 1982.
Sanford A. Miller,
Director, Bureau of Foods.
 [FR Doc. 82-2290 Filed 1-28-82; 8:45 am]
 BILLING CODE 4160-01-M

Office of the Secretary

Office for Civil Rights; Delegation of Authority

Part A, Chapter AT (Office for Civil Rights), section AT.30, Delegations of Authority, of the Statement of Organization, Functions, and Delegations of Authority for the

Department of Health and Human Services (45 FR 47474, July 15, 1980, as amended by 45 FR 82721, December 16, 1980) is amended to include at the end of section AT.30 the following delegation of authority from the Secretary to the Director for Civil Rights, effective December 29, 1981:

10. The civil rights enforcement authority contained in the Health and Human Services Block Grants prescribed by the Omnibus Budget Reconciliation Act of 1981 (Pub. L. 97-35).

Dated: January 24, 1982.
Dale W. Sopper,
Assistant Secretary for Management and Budget.

[FR Doc. 82-2370 Filed 1-28-82; 8:45 am]
 BILLING CODE 4150-04-M

Statement of Organization, Functions, and Delegation of Authority

Part A (Office of the Secretary), Chapter AF (Office of the Inspector General most recently amended in 45 FR 29642-43, May 5, 1980) and Chapter AHP (Office of Personnel, Office of the Assistant Secretary for Personnel Administration most recently amended in 45 FR 72289-90, October 31, 1980) of the Statement of Organization, Functions, and Delegations of Authority are amended to reflect the transfer of personnel system standards of conduct investigations and the internal personnel security program. The personnel system standards of conduct investigation and personnel security functions are being transferred from the Office of the Assistant Secretary for Personnel Administration, Office of Personnel Systems Integrity to the Office of Inspector General, Office of the Assistant Inspector General for Investigations. The changes are as follows:

1. Amend Chapter AHP Office of Personnel, be deleting from Section AHP.20, subsection E.4. Division of Personnel Investigations the following phrase and sentence:

and non-criminal standards-of-conduct cases. Establishes and maintains an internal employee security program, and by inserting instead cases.

2. Amend Chapter AF, Office of Inspector General, Section AF.20 subsection D.1. The Office of Assistant Inspector General for Investigations by adding new paragraphs (g) and (h) to read as follows:

(g) Assess allegations, conducts investigations, and makes recommendations for disposition of personnel system standards-of-conduct cases.

(h) Maintains an internal employee security program.

Dated: January 22, 1982.
Richard S. Schweiker,
Secretary.
 [FR Doc. 82-2369 Filed 1-28-82; 8:45 am]
 BILLING CODE 4150-04-M

DEPARTMENT OF THE INTERIOR

Geological Survey

Oil and Gas and Sulphur Operations in the Outer Continental Shelf; CNG Producing Co.

AGENCY: Geological Survey, Interior.

ACTION: Notice of the receipt of a proposed development and production plan.

SUMMARY: Notice is hereby given that CNG Producing Company has submitted a Development and Production Plan describing the activities it proposes to conduct on Lease OCS-G 4427, Block 318, Vermilion Area, offshore Louisiana.

The purpose of this Notice is to inform the public, pursuant to Section 25 of the OCS Lands Act Amendments of 1978, that the Geological Survey is considering approval of the Plan and that it is available for public review at the Office of the Conservation Manager, Gulf of Mexico OCS Region, U.S. Geological Survey, 3301 North Causeway Blvd., Room 147, Metairie, Louisiana 70002.

FOR FURTHER INFORMATION CONTACT: U.S. Geological Survey, Public Records, Room 147, open weekdays 9 a.m. to 3:30 p.m., 3301 Causeway Blvd., Metairie, Louisiana 70002, Phone (504) 837-44720, Ext. 226.

SUPPLEMENTARY INFORMATION: Revised rules governing practices and procedures under which the U.S. Geological Survey makes information contained in Development and Production Plans available to affected States, executives of affected local governments, and other interested parties became effective December 13, 1979, (44 FR 53685). Those practices and procedures are set out in a revised § 250.34 of Title 30 of the Code of Federal Regulations.

Dated: January 22, 1982.
Lowell G. Hammons,
Conservation Manager, Gulf of Mexico OCS Region.
 [FR Doc. 82-2354 Filed 1-28-82; 8:45 am]
 BILLING CODE 4310-31-M

Oil and Gas and Sulphur Operations in the Outer Continental Shelf; Kerr-McGee Corp.

AGENCY: Geological Survey, Interior.

ACTION: Notice of the receipt of a proposed development and production plan.

SUMMARY: This Notice announces that Kerr-McGee Corporation, Unit Operator of the Ship Shoal Block 28 Federal Unit Agreement No. 14-08-001-2942, submitted on January 7, 1982, a proposed supplement plan of development describing the activities it proposes to conduct on the Ship Shoal Block 28 Federal Unit.

The purpose of this Notice is to inform the public, pursuant to Section 25 of the OCS Lands Act Amendments of 1978, that the Geological Survey is considering approval of the plan and that it is available for public review at the offices of the Conservation Manager, Gulf of Mexico OCS Region, U.S. Geological Survey, 3301 N. Causeway Blvd., Room 147, Metairie, Louisiana 70002.

FOR FURTHER INFORMATION CONTACT: U.S. Geological Survey, Public Records, Room 147, open weekdays 9 a.m. to 3:30 p.m., 3301 N. Causeway Blvd., Metairie, Louisiana 70002, phone (504) 837-4720, ext. 226.

SUPPLEMENTARY INFORMATION: Revised rules governing practices and procedures under which the U.S. Geological Survey makes information contained in development and production plans available to affected States, executives of affected local governments, and other interested parties became effective on December 13, 1979 (44 FR 53685). Those practices and procedure are set out in a revised § 250.34 of Title 30 of the Code of Federal Regulations.

Dated: January 22, 1982.

Lowell G. Hammons,
Conservation Manager, Gulf of Mexico OCS Region.

[FR Doc. 82-2355 Filed 1-28-82; 8:45 am]

BILLING CODE 4310-31-M

Oil and Gas and Sulphur Operations in the Outer Continental Shelf; Tenneco Oil Exploration and Production

AGENCY: Geological Survey, Interior.

ACTION: Notice of the receipt of a proposed development and production plan.

SUMMARY: This Notice announces that Tenneco Oil Exploration and Production, Unit Operator of Vermilion Block 218 Federal Unit Agreement No.

14-08-0001-8816, submitted on January 6, 1982, a proposed annual plan of development/production describing the activities it proposes to conduct on the Vermilion Block 218 Federal Unit.

The purpose of this Notice is to inform the public, pursuant to Section 25 of the OCS Lands Act Amendments of 1978, that the Geological Survey is considering approval of the plan and that it is available for public review at the offices of the Conservation Manager, Gulf of Mexico OCS Region, U.S. Geological Survey, 3301 N. Causeway Blvd., Room 147, Metairie, Louisiana 70002.

FOR FURTHER INFORMATION CONTACT: U.S. Geological Survey, Public Records, Room 147, open weekdays 9:00 a.m. to 3:30 p.m., 3301 N. Causeway Blvd., Metairie, Louisiana 70002, phone (504) 837-4720, ext. 226.

SUPPLEMENTARY INFORMATION: Revised rules governing practices and procedures under which the U.S. Geological Survey makes information contained in development and production plans available to affected States, executives of affected local governments, and other interested parties became effective on December 13, 1979 (44 FR 53685). Those practices and procedures are set out in a revised § 250.34 of Title 30 of the Code of Federal Regulations.

Dated: January 22, 1982.

Lowell G. Hammons,
Conservation Manager, Gulf of Mexico OCS Region.

[FR Doc. 82-2356 Filed 1-28-82; 8:45 am]

BILLING CODE 4310-31-M

Bureau of Land Management

New Mexico Generating Station Environmental Impact Statement; Preparation; Public Meetings

January 22, 1982.

AGENCY: New Mexico State Office, Bureau of Land Management, Interior.

ACTION: Schedule of public meetings to present the proposed action and alternatives of the subject environmental impact statement (EIS).

SUMMARY: The proposed action to be considered includes a proposed 2,000-megawatt coal-fired generating station and ancillary facilities in San Juan County, New Mexico. Included in the proposal are a water delivery system from the San Juan River to the plant site, and two 500 kilovolt transmission lines from the plant site to a proposed substation in Sandoval County, New

Mexico. This proposal was the subject of public meetings held in January and February of 1981.

The public meetings are being held to: (1) Explain the final proposed action; (2) present the alternatives to the proposed action which will be analyzed; and (3) report progress on preparation of the EIS.

ADDRESS: Bureau of Land Management, New Mexico State Office, P.O. Box 1449, Santa Fe, New Mexico 87501.

FOR FURTHER INFORMATION CONTACT: Leslie Cone, Project Manager, Bureau of Land Management, P.O. Box 1449, Santa Fe, New Mexico 87501, Telephone: (505) 988-6467, FTS 476-6467.

SUPPLEMENTARY INFORMATION: Dates, times, and locations of the scheduled meetings are as follows:

Taos, New Mexico; March 2, 1982; 7:00 to 9:00 p.m.; Kachina Lodge
Farmington, New Mexico; March 3, 1982; 7:00 to 9:00 p.m.; Civic Center, Rooms A and B
Albuquerque, New Mexico; March 4, 1982; 7:30 to 9:30 p.m.; Convention Center, Cochiti/Taos Room

Larry L. Woodard,
Acting State Director.

[FR Doc. 82-2353 Filed 1-28-82; 8:45 am]

BILLING CODE 4310-84-M

National Petroleum Reserve—Alaska; Identification and Ranking of Tracts

AGENCY: Bureau of Land Management, Interior.

ACTION: Call for the identification and ranking of tracts.

SUMMARY: The purpose of this notice is to invite interested parties to participate in the ranking of certain oil and gas lease tracts within the National Petroleum Reserve in Alaska (NPR-A) which were cleared for leasing in the Environmental Assessment (EA) published October 1, 1981. In addition, industry is invited to identify (delineate) other tracts within the cleared area which it wishes to have considered for offering at the second NPR-A lease sale scheduled for May 26, 1982.

DATE: Comments must be received by March 1, 1982.

FOR FURTHER INFORMATION CONTACT: Jerry Wickstrom, Anchorage, AK (907) 271-3632.

SUPPLEMENTARY INFORMATION: Interested parties are requested to (a) rank the tracts according to their perceived high, medium and low potential for oil and gas and (b) identify any tracts they believe to have so little potential that they should not be offered in the second lease sale. In addition